SEARCH

SEARCH BY CITATION

References

  • 1
    Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006; 12: 354362.
  • 2
    Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010; CD004064.
  • 3
    Leader M, Collins M, Patel J, Henry K. Vimentin: an evaluation of its role as a tumour marker. Histopathology 1987; 11: 6372.
  • 4
    Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW, Gelmann EP. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res. 1992; 52: 51905197.
  • 5
    Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003; 63: 26582664.
  • 6
    Osborn M, Altmannsberger M, Debus E, Weber K. Differentiation of the major human tumor groups using conventional and monoclonal antibodies specific for individual intermediate filament proteins. Ann NY Acad Sci. 1985; 455: 649668.
  • 7
    Utsunomiya T, Yao T, Masuda K, Tsuneyoshi M. Vimentin-positive adenocarcinomas of the stomach: co-expression of vimentin and cytokeratin. Histopathology 1996; 29: 507516.
  • 8
    Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009; 40: 769777.
  • 9
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of Her2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687697.
  • 10
    Gravalos C, Jimeno A. Her2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008; 19: 15231529.
  • 11
    Tateishi M, Toda T, Minamisono Y, Nagasaki S. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol. 1992; 49: 209212.
  • 12
    Holck S, Pedersen L, Schiodt T, Zedeler K, Mouridsen H. Vimentin expression in 98 breast cancers with medullary features and its prognostic significance. Virchows Arch A Pathol Anat Histopathol. 1993; 422: 475479.
  • 13
    Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res. 2003; 63: 23062311.
  • 14
    Wang L, Zhang J, Banerjee S, Barnes L, Sajja V, Liu Y, Guo B, Du Y, Agarwal MK, Wald DN, et al. Sumoylation of vimentin354 is associated with PIAS3 inhibition of glioma cell migration. Oncotarget. 2010; 1: 620627.
  • 15
    Mergui X, Puiffe ML, Valteau-Couanet D, Lipinski M, Benard J, Amor-Gueret M. p21Waf1 expression is regulated by nuclear intermediate filament vimentin in neuroblastoma. BMC Cancer. 2010; 10: 473.
  • 16
    Amrikachi M, Ro JY, Ordonez NG, Ayala AG. Adenocarcinomas of the gastrointestinal tract with prominent rhabdoid features. Ann Diagn Pathol. 2002; 6: 357363.
  • 17
    Ben-Ze'ev A, Zoller M, Raz A. Differential expression of intermediate filament proteins in metastatic and nonmetastatic variants of the BSp73 tumor. Cancer Res. 1986; 46: 785790.
  • 18
    Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Villette JM, Stower MJ, Maitland NJ. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002; 52: 253263.
  • 19
    Zhao Y, Yan Q, Long X, Chen X, Wang Y. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct. 2008; 26: 571577.
  • 20
    Iwatsuki M, Mimori K, Fukagawa T, Ishii H, Yokobori T, Sasako M, Baba H, Mori M. The clinical significance of vimentin-expressing gastric cancer cells in bone marrow. Ann Surg Oncol. 2010; 7: 25262533.
  • 21
    Kaibara N, Kimura O, Nishidoi H, Makino M, Kawasumi H, Koga S. High incidence of liver metastasis in gastric cancer with medullary growth pattern. J Surg Oncol. 1985; 28: 195198.
  • 22
    McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol. 2010; 4: 404419.
  • 23
    Chen B, Luo RC, Cui F, Qian XY. [Association of HER-2/neu expression with prognosis of gastric cancer]. Nan Fang Yi Ke Da Xue Xue Bao. 2006; 26: 344347.
  • 24
    Cattoretti G, Andreola S, Clemente C, D'Amato L, Rilke F. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer. 1988; 57: 353357.
  • 25
    Jorgensen JT. Targeted Her2 treatment in advanced gastric cancer. Oncology 2010; 78: 2633.